Methods for affecting tissue-resident t cells
AssigneeThe Trustees of the University of Pennsylvania
InventorChristoph T. Ellebrecht
Life of this patent
Estimating the term…
Abstract
Described herein are methods for reducing tissue resident memory T cells (TRM) in the skin, as well as a method for treating, ameliorating, and/or preventing autoimmune and inflammatory diseases or disorders in the skin. These methods include downregulating the expression of GSPT1 in the tissue resident T cells. Also described are methods for screening therapeutic targets for regulating T cell functions.
Claims56
A method of reducing skin-homing T cells or tissue-resident memory T cells (TRM) in a skin tissue, comprising contacting the skin-homing T cells or TRM with an effective amount of a composition that downregulates an expression level and/or an activity of GSPT1.
A method of selectively depleting T cells in the skin, comprising:
- contacting T cells in the skin with a composition that downregulates an expression level and/or an activity of GSPT1.
A method of treating, ameliorating and/or preventing an autoimmune or inflammatory disease or disorder in a skin in a subject in need thereof, comprising:
- administering to the subject an effective amount of a composition that downregulates an expression level and/or an activity of GSPT1.
A pharmaceutical composition, comprising:
- a compound that downregulates an expression level and/or an activity of GSPT1;
- and
- a pharmaceutically acceptable carrier,
- wherein the pharmaceutical composition is formulated as a topical formulation.
A method for treating, ameliorating, and/or preventing an autoimmune or inflammatory disease or disorder in a skin in a subject in need thereof, the method comprising administering an effective amount of the pharmaceutical composition comprising:
- a compound that downregulates an expression level and/or an activity of GSPT1;
- and
- a pharmaceutically acceptable carrier,
- wherein the pharmaceutical composition is formulated as a topical formulation.
A method of screening for therapeutic targets for regulating T cell function in a tissue of interest, comprising:
- preparing a pool of genetically engineered T cells, wherein all or some of the genetically engineered T cells comprises one or more knocked-out or disrupted genes;
- introducing the pool of genetically engineered T cells into a subject carrying the tissue of interest;
- collecting T cells from a plurality of tissues including the tissue of interest;
- detecting genes that are knocked-out or disrupted in the T cells,
- wherein
- a gene is determined to inhibit T cell function in the tissue of interest if the gene is knocked-out or disrupted at a higher rate in T cells in the tissue of interest than in other tissues, or
- a gene is determined to enhance T cell function in the tissue of interest if the gene is knocked-out or disrupted at a lower rate in T cells in the tissue of interest than in other tissues.
Dependencies are inferred from the claim text.